International Stem Cell (ISCO) Interest Expenses (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Interest Expenses of -$110000.0 for Q4 2025, down 382.05% year-over-year from $39000.0 in Q4 2024, and down 121.36% quarter-over-quarter from $515000.0 in Q3 2025.
International Stem Cell (ISCO) Interest Expenses (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Interest Expenses for 16 consecutive years, with -$110000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses fell 382.05% year-over-year to -$110000.0; the TTM figure through Dec 2025 stood at -$135000.0 (down 1600.0% YoY), while the FY2025 annual figure was $7.6 million, up 1.16% from the prior year.
- Interest Expenses slipped to -$110000.0 in Q4 2025 per ISCO's latest filing, from $515000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $720000.0 in Q1 2025 and bottomed at -$110000.0 in Q4 2025.
- Historically, Interest Expenses has averaged $181900.0 across 5 years, with a median of $35500.0 in 2022.
- Annual changes were most pronounced in 2022 — Interest Expenses tumbled 419.35% — and 2024, when it surged 1768.57%.
- International Stem Cell's Interest Expenses stood at $31000.0 in 2021, then sank by 419.35% to -$99000.0 in 2022, then changed by 0.0% to -$99000.0 in 2023, then soared by 139.39% to $39000.0 in 2024, then sank by 382.05% to -$110000.0 in 2025.
- Business Quant data shows ISCO's Interest Expenses at -$110000.0 in Q4 2025, $515000.0 in Q3 2025, and $617000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | 34,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 389,000.00 |
| Jun 30, 2026 | 389,000.00 |
| Dec 31, 2025 | -110,000.00 |
| Dec 31, 2025 | -110,000.00 |
| Sep 30, 2025 | 515,000.00 |
| Sep 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 617,000.00 |
| Jun 30, 2025 | 617,000.00 |
| Mar 31, 2025 | 720,000.00 |
| Mar 31, 2025 | 720,000.00 |
| Dec 31, 2024 | 39,000.00 |
| Dec 31, 2024 | 39,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 654,000.00 |
| Jun 30, 2024 | 654,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Dec 31, 2023 | -99,000.00 |
| Dec 31, 2023 | -99,000.00 |